Caris Life Sciences (CAI) Stock: Buy, Sell, or Hold?
CAI - Caris Life Sciences, Inc. Common Stock
$32.35
1.24 (3.99%)
▲
5d:
+6.92%
30d:
+2.8%
90d:
+106.71%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 04, 2026
12d
Get Alerted When CAI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: CAI shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: CAI shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$18.11
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$11.24
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CAI is currently trading at $32.35, which is considered extended relative to its 30-day fair value range of $28.32 to $31.71. From a valuation perspective, the stock is trading at a premium (Forward PE: 87.0) compared to its historical average (56.0). At these levels, the market is pricing in 15.8% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CAI is in a strong uptrend. The price is approaching resistance at $32.75. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.0% recently.
Market Sentiment: CAI scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CAI is in a strong uptrend. The price is approaching resistance at $32.75. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.0% recently.
Market Sentiment: CAI scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$28.32 -
$31.71
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
27.6%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.0%)
- NEUTRAL: Near Wall St target ($32.23)
- NEUTRAL: Trading at premium valuation - market expects 15.8% growth which is achievable
- WARNING: Composite score 46/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$28.32 -
$31.71
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$25.87
Resistance Level
$32.75
Current Trend
Strong Uptrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
86.99
Wall Street Target
$32.23
(-0.4%)
Revenue Growth (YoY)
45.4%
Profit Margin
10.6%
Valuation Premium vs History
+15.8% premium
PE vs Historical
87.0 vs 56.0
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+15.8%
(market-implied from PE analysis)
1-Year Target
$37.46
(+16%)
2-Year Target
$43.38
(+34%)
3-Year Target
$50.23
(+55%)
3-Yr Target (if PE normalizes)
(PE: 87→56)
PE COMPRESSION
$32.34
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 87.0, Growth: 169.5%)
$109.18
(+238%)
Base:
(SPY PE: 19.9, Growth: 169.5%)
$24.93
(-23%)
Bear:
(PE: 16.9, Growth: 169.5%)
$21.19
(-35%)
📈
Valuation based on Current Earnings
Trailing PE: 18.41 | Current EPS (TTM): $1.69
Bull Case
$17.11
(-47%)
Analyst growth -50.0%, PE expands to 20.3
Base Case
$15.56
(-52%)
Market implied -50.0%, PE stable at 18.4
Bear Case
$21.15
(-35%)
Severe decline -20.0%, PE contracts to 15.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 22, 2026 7:44 AM ET
Data refreshes hourly during market hours. Next update: 8:44 AM
Data refreshes hourly during market hours. Next update: 8:44 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CAI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
STRONG BUY
32 analysts |
$571 | 50 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$369 | 50 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
21 analysts |
$307 | 51 HOLD |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$75 | 70 BUY |
|
KURA
Kura Oncology Inc |
STRONG BUY
16 analysts |
$32 | 62 BUY |